Table 2. Tumour and patient analyses for ablation effectiveness and local tumour progression.
| Factors | MP (n=101 patients with 129 tumours) | LP (n=46 patients with 61 tumours) | p-value |
| Follow-up (months)a | 21.30±8.30 | 19.78±6.53 | 0.277 |
| Hospital stay (days)a | 4.42±3.68 | 3.50±2.73 | 0.181 |
| Meperidine (mg dl–1)a | 51.63±20.58 | 57.07±18.31 | 0.127 |
| Midazolam (mg dl–1)a | 4.90±2.17 | 5.39±1.78 | 0.177 |
| Complete ablation after 1 session | 98 (76.0%) | 43 (70.5%) | 0.478 |
| Primary effectiveness | 116 (89.9%) | 56 (91.8%) | 0.795 |
| LTP | 38 (29.5%) | 19 (31.1%) | 0.866 |
| Time to LTP (months)a | 11.08±6.8 | 9.16±7.96 | 0.346 |
| Subanalysis for RF ablation using internally cooled electrode | |||
| MP (n=107 tumours) | LP (n=54 tumours) | ||
| Cool-down number | 16.61±15.57 | 7.59±7.94 | <0.001 |
| Cool-down temperature (°C)a | 74.72±7.51 | 74.49±9.42 | 0.870 |
LP, low power; LTP, local tumour progression; MP, maximal power.
aData expressed as mean±standard deviation.